Pfizer Inc. (NYSE:PFE) Shares Bought by Cullen Capital Management LLC

Cullen Capital Management LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 12.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,774,380 shares of the biopharmaceutical company’s stock after buying an additional 545,406 shares during the period. Cullen Capital Management LLC’s holdings in Pfizer were worth $126,664,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in PFE. Norges Bank purchased a new position in Pfizer during the fourth quarter valued at $2,328,986,000. Charles Schwab Investment Management Inc. lifted its stake in Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after buying an additional 25,315,159 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Pfizer in the 4th quarter worth about $274,694,000. Massachusetts Financial Services Co. MA increased its stake in Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after buying an additional 5,350,381 shares in the last quarter. Finally, Fisher Asset Management LLC raised its holdings in shares of Pfizer by 79.5% during the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company’s stock valued at $295,760,000 after acquiring an additional 4,938,209 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on PFE shares. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Trading Down 5.4 %

NYSE:PFE opened at $22.99 on Friday. Pfizer Inc. has a 12-month low of $22.95 and a 12-month high of $31.54. The firm has a market cap of $130.39 billion, a PE ratio of 16.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a fifty day moving average price of $25.87 and a 200 day moving average price of $26.76.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the business posted $0.10 EPS. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.